The current PE ratio for Collegium Pharmaceutical stock as of Feb 7, 2025 is 11.37. This is calculated based on the current EPS of $2.71 and the stock price of $30.82 per share. The P/E ratio has a decrease of 24% from the past four quarters average of 15.1.
The average historical PE ratio of Collegium Pharmaceutical for the last five years is 22.73. The current PE ratio of 11.37 is 50% below the historical average. Over the past five years, COLL's PE ratio was at its highest in the Sep 2023 quarter at 85.96, when the stock price was $22.35 and the EPS was $0.26. The lowest value was in the Sep 2021 quarter, when it reached 6.71 with a price of $19.74 and an EPS of $2.94.
Maximum annual decrease: -64.52% in 2021
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | 21.52 | N/A | $30.78 | $1.43 |
2022 | N/A | N/A | $23.2 | -$0.74 |
2021 | 9.11 | -64.52% | $18.68 | $2.05 |
2020 | 25.68 | N/A | $20.03 | $0.78 |
2019 | N/A | N/A | $20.58 | -$0.68 |
2018 | N/A | N/A | $17.17 | -$1.19 |
2017 | N/A | N/A | $18.46 | -$2.47 |
2016 | N/A | N/A | $15.57 | -$3.88 |
2015 | N/A | N/A | $27.5 | -$1.48 |
2014 | N/A | N/A | N/A | -$22.72 |
2013 | N/A | N/A | N/A | -$4.06 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | 14.26 | 34.15% | $38.64 | $2.71 |
Jun 2024 | 10.63 | -23.03% | $32.2 | $3.03 |
Mar 2024 | 13.81 | -35.83% | $38.82 | $2.81 |
Dec 2023 | 21.52 | -74.97% | $30.78 | $1.43 |
Sep 2023 | 85.96 | N/A | $22.35 | $0.26 |
Jun 2023 | N/A | N/A | $21.49 | -$0.34 |
Mar 2023 | N/A | N/A | $23.99 | -$0.87 |
Dec 2022 | N/A | N/A | $23.2 | -$0.74 |
Sep 2022 | N/A | N/A | $16.02 | -$1.22 |
Jun 2022 | N/A | N/A | $17.72 | -$1 |
Mar 2022 | 16.83 | 84.74% | $20.36 | $1.21 |
Dec 2021 | 9.11 | 35.77% | $18.68 | $2.05 |
Sep 2021 | 6.71 | -13.75% | $19.74 | $2.94 |
Jun 2021 | 7.78 | -60.29% | $23.64 | $3.04 |
Mar 2021 | 19.59 | -23.71% | $23.7 | $1.21 |
Currently, COLL's PE ratio is below the 3 and 5-year averages.
COLL's PE ratio is lower than its peer stocks UTHR and SUPN.
Stock name | PE ratio | Market cap |
---|---|---|
COLL Collegium Pharmaceutical Inc | 11.37 | $993.95M |
UTHR UNITED THERAPEUTICS Corp | 14.3 | $15.52B |
SUPN Supernus Pharmaceuticals Inc | 35.56 | $2.12B |
LPCN Lipocine Inc | N/A | $18.72M |
COLL stock has a price to earnings ratio of 11.37 as of Feb 7, 2025.
The average PE ratio for COLL stock over the past 3 years is 27.17.
The average PE ratio for COLL stock over the past 5 years is 22.73.
In the last five years, the Sep 2023 quarter recorded the highest quarterly PE ratio at 85.96.
The current price to earnings ratio of COLL is 50% lower than the 5-year historical average.
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (Feb 7, 2025), Collegium Pharmaceutical's stock price is $30.82. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $2.71. Therefore, Collegium Pharmaceutical's P/E ratio for today is 11.37. PE RATIO(11.37) = STOCK PRICE($30.82) / TTM EPS($2.71)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.